Table 1.

Study characteristics of included studies for prevalence and timing of de-escalation

Study	Design	Country	Study N	Ticagrelor group (n)	Timing of de-escalation—with reasonsa
Angeras et al. [25]	Retrospective Cohort	Sweden	1,04,012	Ticagrelor + aspirin (n = 11,680)	After discharge—NR
Biscaglia et al. [26]	Prospective Cohort	Italy	586	Ticagrelorb (n = 586)	Varied—need for OAT, bleeding, intolerance, unwillingness, dyspnea
Coons et al. [27]	Retrospective Cohort	United States	8127	Ticagrelorb (n = 309)	In-hospital—NR
Dehghani et al. [28]	Prospective Cohort	Canada	227	Ticagrelorb (n = 227)	Varied—dyspnea, no coverage, significant bleeding
Dery et al. [29]	Prospective Cohort	Canada	2179	Ticagrelorb (n = 242/241c)	At discharge—NR
Gaubert et al. [30]	Prospective Cohort	France	164	Ticagrelorb (n = 164)	After discharge—NR
Green et al. [31]	Retrospective Cohort	Denmark	7016	Ticagrelorb (n = 3159/3066c)	After discharge—NR
Hamid [32]	Retrospective Cohort	United Kingdom	98	Ticagrelor + aspirin (n = 98)	After discharge—NR
Harding et al. [33]	Prospective Cohort	New Zealand	992	Ticagrelor + aspirin (n = 243)	Varied—NR
Simeone et al. [34]	Retrospective Cohort	United States	15,788	Ticagrelorb (n = 2323)	After discharge—NR
Wang et al. [35]	Prospective Cohort	China	417	Ticagrelor + aspirin (n = 99)	In-hospital or at discharge—NR
Zettler et al. [36]	Prospective Cohort	United States	8672	Ticagrelorb (n = 226)	After discharge—NR

NR not reported, OAT oral anticoagulant

^aReasons reported in at least 10% of those who de-escalated are listed

^bStudy did not clearly specify whether all patients also received aspirin

^cNumber of patients enrolled/number of patients analyzed